Oculus Announces Confidential Submission of Draft Registration Statement for Initial Public Offering to Securities and Exchange

Oculus Announces Confidential Submission of Draft Registration Statement for
Initial Public Offering to Securities and Exchange Commission by Its
Subsidiary Ruthigen, Inc.

PETALUMA, Calif., May 28, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences,
Inc. (the "Company") (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries, today announced that Ruthigen, Inc., a wholly owned subsidiary of
the company ("Ruthigen"), submitted a draft registration statement on a
confidential basis to the U.S. Securities and Exchange Commission for a
possible initial public offering of Ruthigen common stock.The number of
shares to be offered and the price range for the offering have not yet been
determined.

This press release is being issued pursuant to and in accordance with Rule 135
under the Securities Act of 1933, as amended. As required by Rule 135, this
press release does not constitute an offer to sell or the solicitation of an
offer to buy securities, and shall not constitute an offer, solicitation or
sale in any jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities laws of
that jurisdiction.

Forward-Looking Statements

Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are identified by the use of words such as "possible" and
"determined," among others. Forward-looking statements in this press release
are subject to certain risks and uncertainties that could cause actual results
to vary, including,but not limited to, the statements regarding the purposes
of the proposed initial public offering, market conditions, Ruthigen's ability
to complete the proposed initial public offering, the clearance by the
relevant regulators of the regulatory filings of Ruthigen relating to the
proposed initial public offering and the other risks set forth in the
Ruthigen's filings with the U.S. Securities and Exchange Commission. Neither
Ruthigen nor Company undertake any obligation to update these forward-looking
statements, except as required by law.

CONTACT: Media and Investor Contact:

         Oculus Innovative Sciences, Inc.
         Dan McFadden
         VP of Public and Investor Relations
         (425) 753-2105
         dmcfadden@oculusis.com
        
         Ruthigen Inc.
         Sameer Harish
         Chief Financial Officer
         sharish@ruthigen.com